报价延迟最少15分钟:2025/07/20 15:16 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
4.18 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-0.64/-1.23
|
|
企业价值
168.77M
|
| 资产负债 |
|
每股账面净值
0.79
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟：2025/07/20 15:16 EDT
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis. |
